STOCK TITAN

Si-Bone - SIBN STOCK NEWS

Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.

Company Overview

Si-Bone Inc. is a specialized medical device company with a focused mission to improve patient outcomes in the realm of orthopedic surgery, particularly in the treatment of sacroiliac joint dysfunction. As a pioneer in the field, Si-Bone has developed a proprietary, minimally invasive implant system aimed at facilitating sacroiliac joint fusion. Leveraging patents for titanium implant technologies, the company has made significant strides in reducing the invasiveness of traditional sacroiliac joint fusion procedures.

Core Business and Innovation

At the heart of its operations, Si-Bone’s innovative approach is encapsulated in its iFuse Implant System, which is designed to provide a reliable alternative to conventional surgical techniques. The company has successfully combined advanced engineering with practical surgical approaches to produce a system that addresses complex conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, and pelvic trauma. The product portfolio includes instruments and implantable bone products that facilitate the fusion process during minimally invasive procedures, creating a distinct market niche with several industry-specific keywords such as minimally invasive surgery, orthopedic implants, and joint fusion.

Technological Advancements

Si-Bone separates itself from competitors through its commitment to technological innovation. The iFuse Implant System, along with its variations such as iFuse-TORQ and iFuse Bedrock Granite, incorporates breakthrough design and engineering principles to ensure safety and efficacy within complex anatomical regions. These devices are supported by rigorous clinical research and designed to provide enhanced pelvic fixation, particularly during concurrent lumbar spinal fusion procedures. This focus on precision technology underscores the company’s strategic positioning within the medical device market.

Clinical and Surgical Impact

The clinical implications of Si-Bone’s technology are noteworthy, especially for patients who have traditionally faced limited treatment options in the context of sacroiliac joint dysfunction. The minimally invasive nature of the iFuse Implant System offers advantages such as reduced recovery times, fewer complications compared to traditional open surgery, and a more targeted approach in addressing structural conditions. By improving the procedural experience for both patients and surgeons, Si-Bone plays a critical role in evolving standards of care in orthopedic surgery.

Market Position and Competitive Landscape

Si-Bone operates within a highly specialized sector of the medical device industry, marked by its focus on orthopedic applications. The company’s targeted approach to sacroiliac fusion procedures and its suite of patented implant products have carved a niche in an industry characterized by continuous innovation and rigorous safety standards. While there are other players in the broader field of orthopedic devices, Si-Bone differentiates itself by addressing the challenges associated with under-diagnosed and under-treated sacroiliac joint conditions using less invasive methods. The company’s seasoned management team, with experience from major industry names, further reinforces its authority and capability in driving orthopedic innovation.

Operational Excellence and Quality Assurance

Operating under stringent regulatory frameworks, Si-Bone emphasizes both the safety and effectiveness of its implant systems. The company’s operational strategy combines deep clinical expertise with advanced technological design, ensuring each product meets high standards of quality and efficacy. By integrating comprehensive research and development with real-world surgical feedback, Si-Bone is able to continuously refine its products, aiming to maintain robust patient safety profiles and reliable clinical outcomes.

Expertise and Industry Recognition

Si-Bone’s standing in the orthopedic device community is bolstered by its innovative approaches and the robust clinical data supporting its technologies. The company’s adoption of breakthrough design methods and its ability to translate complex medical needs into effective surgical solutions showcase its technical expertise. For healthcare professionals, patients, and stakeholders, Si-Bone represents a blend of advanced engineering, clinical precision, and a commitment to minimally invasive treatment paradigms, making it a respected name within its competitive landscape.

Comprehensive Product Portfolio

The diverse portfolio from Si-Bone is characterized by a range of implant systems designed to address various orthopedic conditions. It includes systems that directly target sacroiliac joint fusion as well as those that serve broader applications such as adjacent spinal conditions and pelvic trauma. This diversified approach allows clinicians to select devices tailored to the specific needs of their patients while maintaining consistency in surgical outcomes.

Conclusion

In summary, Si-Bone Inc. is an innovator in the orthopedic medical device space, focused on developing minimally invasive, patented implant systems for sacroiliac joint fusion and related applications. Through its continuous commitment to research, quality assurance, and operational precision, the company has established a strong market presence and a clear value proposition within a niche yet critically important segment of orthopedics. Its pioneering technologies, underscored by substantial clinical validation and a robust product portfolio, position it as an informative case study for anyone seeking a deep understanding of advanced orthopedic solutions.

Rhea-AI Summary
SI-BONE, Inc. (SIBN) reported strong financial results for Q4 and FY 2023, with worldwide revenue up by ~22% and ~31% respectively. The company achieved gross margins of ~74% in Q4 and ~79% in FY 2023. Despite an increase in operating expenses, the net loss improved by ~2% in Q4 and ~29% for the year. Adjusted EBITDA loss declined by ~16% in Q4 and ~48% for FY 2023. Cash and equivalents stood at ~$166 million as of December 31, 2023. The company expects a 17% to 19% year-over-year revenue growth for 2024, with a gross margin of ~78% and operating expenses growth of ~9%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.53%
Tags
-
Rhea-AI Summary
SI-BONE, Inc. (SIBN) will report financial results for Q4 and full year 2023 on February 26, 2024. The company specializes in medical devices for musculoskeletal disorders. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET, with the webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences earnings
-
Rhea-AI Summary
SI-BONE, Inc. (SIBN) announces FDA 510(k) premarket clearance for the iFuse Bedrock Granite Implant System, expanding its indication in pediatric patients and application in the S1 trajectory. The Granite implant provides sacroiliac fusion and sacropelvic fixation, with a smaller 9.5 mm diameter option. The system was also awarded Breakthrough Device Designation and New Technology Add-on Payment. Medical professionals express excitement about the potential benefits of the new implant system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
Rhea-AI Summary
SI-BONE, Inc. (SIBN) announces preliminary and unaudited revenue for the fourth quarter and full year 2023, with worldwide revenue expected to be in the range of $138.5-138.7 million, representing growth of approximately 30% compared to the prior year period. U.S. revenue is expected to be in the range of $130.5-$130.6 million, with cash and marketable securities expected to be approximately $166.0 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
none
-
Rhea-AI Summary
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the Piper Sandler Healthcare Conference in New York. The company's management will host a fireside chat on November 28, 2023, at 3:30 p.m. ET. Interested investors can register to listen to the conference call via a provided link. The webcast will be available on the company's website and archived for at least 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
conferences
-
Rhea-AI Summary
SI-BONE, Inc. (Nasdaq:SIBN) reported financial results for Q3 2023, with record worldwide revenue of $34.0 million, representing approximately 29% growth over the same period in 2022. U.S. revenue reached $32.3 million, a 31% increase. Gross margin was approximately 79%. The company also received a patent for a crucial technology and surpassed 90,000 procedures performed worldwide. Annual guidance has been increased to $136 million - $137 million, implying annual growth of 28%-29%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
Rhea-AI Summary
SI-BONE, Inc. will be participating in the Jefferies London Healthcare Conference on November 15, 2023. The company will host a fireside chat at 4:00 a.m. ET / 1:00 a.m. PT. Investors can register to listen to the conference call via a provided link. The webcast will be available on the company's website and archived for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
-
Rhea-AI Summary
SI-BONE, Inc. to report Q3 2023 financial results on November 6, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
conferences earnings
-
Rhea-AI Summary
SI-BONE confirms compatibility of certain Medtronic Solera rods with iFuse Bedrock Granite implant, boosting confidence in its leading pelvic fixation implant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
Rhea-AI Summary
SI-BONE, Inc. to participate in Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
conferences

FAQ

What is the current stock price of Si-Bone (SIBN)?

The current stock price of Si-Bone (SIBN) is $13.45 as of April 21, 2025.

What is the market cap of Si-Bone (SIBN)?

The market cap of Si-Bone (SIBN) is approximately 567.2M.

What is the primary focus of Si-Bone?

Si-Bone specializes in developing and commercializing innovative, minimally invasive implant systems designed for sacroiliac joint fusion, addressing complex orthopedic conditions.

How does the iFuse Implant System benefit patients?

The iFuse Implant System offers a less invasive alternative to traditional sacroiliac joint fusion surgery, resulting in reduced recovery times and potentially fewer complications.

What types of conditions does Si-Bone target with its products?

Si-Bone addresses conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, pelvic trauma, and specific challenges associated with spinal deformity.

How does Si-Bone differentiate itself in the orthopedic device industry?

Si-Bone differentiates itself by focusing on a niche market with its patented, minimally invasive technologies and by leveraging a management team with deep industry expertise from leading orthopedic companies.

What are the key benefits of minimally invasive surgical systems?

Minimally invasive systems typically provide improved patient recovery experiences, reduced overall surgical trauma, and enhanced precision during implant procedures, which are all hallmarks of Si-Bone's approach.

How does Si-Bone ensure the quality and safety of its products?

Si-Bone integrates rigorous clinical research and strict quality assurance protocols into its design and manufacturing process, ensuring that its implant systems meet high standards of safety and efficacy.
Si-Bone

Nasdaq:SIBN

SIBN Rankings

SIBN Stock Data

567.17M
37.46M
3.09%
95.51%
2.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA